A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

December 31, 2011

Conditions
Biliary Tract Cancer
Interventions
DRUG

"Bevacizumab in combination with modified FOLFOX6."

Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay \> 4 weeks

Trial Locations (1)

20007

Georgetown University Medical Center, Washington D.C.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Georgetown University

OTHER

NCT00881504 - A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma | Biotech Hunter | Biotech Hunter